Compare CHOW & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHOW | COCP |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | Hong Kong | United States |
| Employees | 17 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1M | 14.1M |
| IPO Year | N/A | 2011 |
| Metric | CHOW | COCP |
|---|---|---|
| Price | $0.38 | $1.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 10.2M | 80.1K |
| Earning Date | 06-17-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.86 |
| 52 Week High | $12.05 | $2.19 |
| Indicator | CHOW | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 44.66 | 46.42 |
| Support Level | $0.34 | $0.99 |
| Resistance Level | $0.52 | $1.11 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 4.18 | 71.43 |
ChowChow Cloud International Holdings Ltd provides one-stop cloud solutions that support companies across the IT industry value chain throughout their entire cloud transformation journey, from consulting, deployment, and migration to cloud environment building and management. Its business comprises (i) digital transformation consulting services consisting of cloud suitability assessment, (ii) professional IT services comprising capabilities designed to facilitate seamless cloud integration and digital transformation, (iii) AI-powered proactive cloud managed services covering all aspects of day-to-day cloud maintenance and support, and (iv) IT infrastructure solutions covering on-premise private cloud setups and public cloud integrations, including infrastructure applications.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.